Literature DB >> 10201773

Liver metastases after curative resection in patients with distal bile duct cancer.

S Takao1, H Shinchi, K Uchikura, M Kubo, T Aikou.   

Abstract

BACKGROUND: Curative resection cannot ensure long-term survival for patients with distal bile duct cancer. The aim of this study was to determine the most frequent mode of recurrence after curative resection and to analyse its risk factors.
METHODS: Clinical details for 64 consecutive patients with distal bile duct cancer who underwent surgical resection between 1980 and 1997 were reviewed. Modes of recurrence and clinicopathological findings were analysed based on the residual tumour (R) classification.
RESULTS: The overall actuarial 5-year survival rate was 32 per cent. Of 42 patients undergoing R0 resection 10 were alive at 5 years, of 17 having R1 resection one was alive at 5 years, and none of the five patients having R2 resection survived for 5 years (R0 versus R1, P = 0.02). In the R0 group, the incidence of liver recurrence (14 of 42 patients) was similar to that in the R1 resection group (six of 17), although there were fewer lymph node and peritoneal recurrences than in patients who had R1 resection (P < 0.05). The high-risk factor for liver metastasis was microscopic vascular involvement. Important factors for survival were lymph node metastasis, microscopic vascular involvement and age. In addition, microscopic vascular involvement was the only independent factor for survival in the R0 group.
CONCLUSION: R0 resection provided significant survival benefit but had no effect on liver recurrence. Therefore, new agents or strategies to prevent liver metastasis are necessary for improvement of survival.

Entities:  

Mesh:

Year:  1999        PMID: 10201773     DOI: 10.1046/j.1365-2168.1999.01018.x

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  8 in total

1.  Metastatic lymph nodes in hilar cholangiocarcinoma: does size matter?

Authors:  Anthony T Ruys; Fiebo J W Ten Kate; Olivier R Busch; Marc R Engelbrecht; Dirk J Gouma; Thomas M van Gulik
Journal:  HPB (Oxford)       Date:  2011-09-26       Impact factor: 3.647

2.  Survival Benefits of Surgical Resection in Patients with Recurrent Biliary Tract Carcinoma.

Authors:  Hiroaki Motoyama; Akira Kobayashi; Takahide Yokoyama; Akira Shimizu; Noriyuki Kitagawa; Tsuyoshi Notake; Kentaro Fukushima; Hitoshi Masuo; Takahiro Yoshizawa; Shin-Ichi Miyagawa
Journal:  World J Surg       Date:  2017-11       Impact factor: 3.352

3.  Metastasis to the skin at the drain site after complete resection of the lower bile duct cancer: report of a case.

Authors:  Takuji Noro; Hironori Ohdaira; Reo Takizawa; Naruo Kawasaki; Masaki Kitajima; Yutaka Suzuki
Journal:  Surg Today       Date:  2012-09-29       Impact factor: 2.549

4.  Hepatic resection for liver metastases from carcinomas of the distal bile duct and of the papilla of Vater.

Authors:  Isao Kurosaki; Masahiro Minagawa; Chie Kitami; Kabuto Takano; Katsuyoshi Hatakeyama
Journal:  Langenbecks Arch Surg       Date:  2011-02-24       Impact factor: 3.445

5.  Anatomic patterns of recurrence in biliary tract cancers: does primary tumor site matter?

Authors:  Andrew J Sinnamon; Anthony C Wood; Megan A Satyadi; Catherine V Levitt; Olivia Hardy; Mintallah Haider; Richard D Kim; Daniel A Anaya; Jason W Denbo
Journal:  J Gastrointest Oncol       Date:  2022-06

6.  Surgery for extrahepatic cholangiocarcinoma: predictors of survival.

Authors:  J J Kloek; F J Ten Kate; O R C Busch; D J Gouma; T M van Gulik
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

7.  Predictive Factors of Early Recurrence in Patients with Distal Cholangiocarcinoma after Pancreaticoduodenectomy.

Authors:  Yasuhiro Ito; Yuta Abe; Tomohisa Egawa; Minoru Kitago; Osamu Itano; Yuko Kitagawa
Journal:  Gastroenterol Res Pract       Date:  2018-04-03       Impact factor: 2.260

8.  Endobiliary radiofrequency ablation for distal extrahepatic cholangiocarcinoma: A clinicopathological study.

Authors:  Eui Joo Kim; Dong Hae Chung; Yoon Jae Kim; Yeon Suk Kim; Yeon Ho Park; Keon Kuk Kim; Jae Hee Cho
Journal:  PLoS One       Date:  2018-11-15       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.